Halberd Corporation (OTC: HALB) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU. The testing will focus on Halberd’s patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI). The work will be conducted under the direction of Dr. Russell Carr, of the College of Veterinary Medicine, as the Principal Investigator.